Humanigen to Begin Phase 3 Trial of Lenzilumab for COVID-19 in Brazil

Brazil’s health agency has approved a phase 3 trial of Humanigen’s lenzilumab for the treatment of COVID-19 patients.

The trial in adults hospitalized with severe and critical COVID-19 at high risk of disease progression is an expansion of the company’s phase 3 study of the drug in the U.S.

Lenzilumab was selected last month for the National Institutes of Health’s Big Effect Trial, a separate study of the drug in combination with remdesivir for the treatment of hospitalized COVID-19 patients.